Schjesvold Fredrik (Fredrik H Schjesvold, Fredrik Schjesvold)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 31

Top Topics

Multiple Myeloma

Hodgkin Lymphoma

Silver Nanoparticles

Top Venues

Blood cancer journal

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Anu Partanen, Anders Waage, Valdas Peceliunas, Schjesvold Fredrik, Pekka Anttila, Marjaana Säily, Katarina Uttervall, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Ronald Svensson, Per Axelsson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoysaeter Fenstad, Sorella Ilveskero, Tarja-Terttu Pelliniemi, Hareth Nahi, Raija Silvennoinen
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers 16 (5) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Charlotte Pawlyn, Schjesvold Fredrik, David A Cairns, L J Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos-Manteca, Jacob P Laubach, Katja C Weisel, Heinz Ludwig, Sundararajan Vincent Rajkumar, Pieter Sonneveld, Graham H Jackson, Gareth Morgan, Paul Gerard Richardson
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood cancer journal 14 (1) (2024)
Charlotte Pawlyn, Schjesvold Fredrik, David A Cairns, L J Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos-Manteca, Jacob P Laubach, Katja C Weisel, Heinz Ludwig, Sundararajan Vincent Rajkumar, Pieter Sonneveld, Graham H Jackson, Gareth Morgan, Paul Gerard Richardson
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood cancer journal 14 (1) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Anu Partanen, Anders Waage, Valdas Peceliunas, Schjesvold Fredrik, Pekka Anttila, Marjaana Säily, Katarina Uttervall, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Ronald Svensson, Per Axelsson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoysaeter Fenstad, Sorella Ilveskero, Tarja-Terttu Pelliniemi, Hareth Nahi, Raija Silvennoinen
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers 16 (5) (2024)
Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Schjesvold Fredrik, null null
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal 14 (1) (2024)
Charlotte Pawlyn, Schjesvold Fredrik, David A Cairns, L J Wei, Faith Davies, Omar Nadeem, Haifaa Abdulhaq, Maria-Victoria Mateos-Manteca, Jacob P Laubach, Katja C Weisel, Heinz Ludwig, Sundararajan Vincent Rajkumar, Pieter Sonneveld, Graham H Jackson, Gareth Morgan, Paul Gerard Richardson
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood cancer journal 14 (1) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Nordberg Nørgaard Jakob, Kari Lenita Falck Moore, Tobias Schmidt Slørdahl, Anders Vik, Tor Henrik Anderson Tvedt, Schjesvold Fredrik
VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study. Blood cancer journal 14 (1) (2024)
Schjesvold Fredrik, Heinz Ludwig, Maria-Victoria Mateos-Manteca, Alessandra Larocca, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A Bakker, Paul Gerard Richardson, Pieter Sonneveld
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. European journal of haematology (2023)
Nordberg Nørgaard Jakob, Niels Abildgaard, Anna Lysén, Galina Tsykunova, Annette Juul Vangsted, Cristina Joao, Nora Remen, Lene Kongsgaard Nielsen, Liv Osnes, Caroline Stokke, James P Connelly, Mona-Elisabeth R Revheim, null null, Schjesvold Fredrik
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation. Leukemia (2023)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Michel Delforge, Curly T C M Morris, Francesca Gay, Niels W C J van de Donk, Ioannis Ntanasis-Stathopoulos, Annette Juul Vangsted, Christoph Driessen, Schjesvold Fredrik, Claudio Cerchione, Sonja Zweegman, Roman Hájek, Phillipe Moreau, Hermann Einsele, Jesús San F Miguel, Mario Boccadoro, Meletios- Athanasios Dimopoulos, Pieter Sonneveld, Heinz Ludwig
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia (2023)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, Michel Delforge, Curly T C M Morris, Francesca Gay, Niels W C J van de Donk, Ioannis Ntanasis-Stathopoulos, Annette Juul Vangsted, Christoph Driessen, Schjesvold Fredrik, Claudio Cerchione, Sonja Zweegman, Roman Hájek, Phillipe Moreau, Hermann Einsele, Jesús San F Miguel, Mario Boccadoro, Meletios- Athanasios Dimopoulos, Pieter Sonneveld, Heinz Ludwig
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia (2023)
Marc-Steffen Raab, Elena Zamagni, Salomon Manier, Paula Rodriguez Otero, Schjesvold Fredrik, Annemiek Broijl
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results. EJHaem 4 (4) (2023)
Marc-Steffen Raab, Yael C Cohen, Schjesvold Fredrik, Kimberly Aardalen, Adwait Oka, Andrew Spencer, Martin Wermke, Anita D Souza, Jonathan L Kaufman, Anna Maria Cafro, Enrique María Ocio, Noriko Doki, Kristin Henson, Gina Trabucco, Ana Carrion, Florent C Bender, Pierre-Eric Juif, Adonai Fessehatsion, Liqiong Fan, Jeffrey P Stonehouse, John W Blankenship, Brian Granda, Serena De Vita, Haihui Lu
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia (2023)
Michael T Gundesen, Jon Thor Asmussen, Schjesvold Fredrik, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Thomas Lund, null null
Potential value of pre-planned imaging of bone disease in multiple myeloma. Blood cancer journal 13 (1) (2023)
Meletios- Athanasios Dimopoulos, Schjesvold Fredrik, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Yolanda Gonzalez Montes, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf Henrik Mellqvist, Roland Fenk, Hélène Demarquette, Hamdi Sati, Alexander Vorog, Richard Labotka, Jichang Du, Mohamed Darif, Shaji K Kumar
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial. Blood cancer journal 12 (1) (2022)
Michael T Gundesen, Jon T Asmussen, Einar Haukås, Michael Schubert, Niels Abildgaard, Schjesvold Fredrik, Thomas Lund
A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma. European journal of haematology 108 (5) (2022)
Schjesvold Fredrik, Sara Bringhen, Paul Gerard Richardson, Aurore Perrot, Xavier Leleu, Phillipe Moreau, Meletios- Athanasios Dimopoulos, Cyrille Hulin, Christina Tekle, Meredith C Foster, Elizabeth M Poole, Helgi van de Velde, Thierry Facon
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. American journal of hematology 96 (11) (2021)
Carlos Fernández de Larrea, Robert Kyle, Laura Rosinol, Juan José Lahuerta, Monika Engelhardt, Saad Z Usmani, Jo Caers, Wilson Gonsalves, Schjesvold Fredrik, Giampaolo Merlini, Suzanne Lentzch, Enrique Ocio, Laurent Garderet, Philippe Moreau, Pieter Sonneveld, Ashraf Badros, Gösta Gahrton, Hartmut Goldschmidt, Sascha A Tuchman, Hermann Einsele, Brian Durie, Baldeep Wirk, Pellegrino Musto, Patrick Hayden, Martin F Kaiser, Jesús San F Miguel, Joan Bladé, Sundararajan Vincent Rajkumar, Maria-Victoria Mateos-Manteca
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood cancer journal 11 (12) (2021)
Henrik Gregersen, Valdas Peceliunas, Kari Remes, Schjesvold Fredrik, Niels Abildgaard, Hareth Nahi, Niels Frost Andersen, Annette Juul Vangsted, Tobias Wirenfeldt Klausen, Carsten Helleberg, Kristina Carlson, Ulf Christian Frølund, Per Axelsson, Olga Stromberg, Cecilie Hveding Blimark, Jacob Crafoord, Galina Tsykunova, Henrik Rode Eshoj, Anders Waage, Markus Hansson, Nina Gulbrandsen
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. European journal of haematology 108 (1) (2021)
Schjesvold Fredrik, Albert Oriol
Current and Novel Alkylators in Multiple Myeloma. Cancers 13 (10) (2021)
Jonathan L Kaufman, Cristina Gasparetto, Schjesvold Fredrik, Phillipe Moreau, Cyrille Touzeau, Thierry Facon, Lawrence H Boise, Yanwen Jiang, Xiaoqing Yang, Fengjiao Dunbar, Deeksha Vishwamitra, Stefanie Unger, Tammy Macartney, John Pesko, Yao Yu, Ahmed Hamed Salem, Jeremy A Ross, Wan-Jen Hong, Paulo C Maciag, James M Pauff, Shaji Kumar
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American journal of hematology 96 (4) (2021)
Paul G Richardson, Schjesvold Fredrik, Katja Weisel, Phillipe Moreau, Larry D Anderson, Darrell White, Paula Rodriguez-Otero, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Meral Beksac, Albert Ortiol, Jindriska Lindsay, Anna Marina Liberati, Monica Galli, Pawel Robak, Alessandra Larocca, Munci Yagci, Filiz Vural, Abraham S Kanate, Ruiyun Jiang, Lara Grote, Teresa Peluso, Meletios- Athanasios Dimopoulos
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. European journal of haematology 108 (1) (2021)
Nordberg Nørgaard Jakob, Bugge Askeland Frida, Geir Erland Tjønnfjord, Schjesvold Fredrik
Neoplastic plasma cells with Auer rod-like inclusions. EJHaem 1 (1) (2020)
Schjesvold Fredrik, Hartmut Goldschmidt, Vladimir Maisnar, Ivan Spicka, Neils Abildgaard, Philip Rowlings, Lauren Cain, Dorothy Romanus, Kaveri Suryanarayan, Vincent Rajkumar, Dawn Odom, Ari Gnanasakthy, Meletios- Athanasios Dimopoulos
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. European journal of haematology 104 (5) (2020)
Schjesvold Fredrik
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. European journal of haematology 105 (4) (2020)